These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22016143)

  • 1. Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London.
    Kohut K; D'Mello L; Bancroft EK; Thomas S; Young MA; Myhill K; Shanley S; Briggs BH; Newman M; Saraf IM; Cox P; Scambler S; Wagman L; Wyndham MT; Eeles RA; Ferris M
    Fam Cancer; 2012 Mar; 11(1):107-13. PubMed ID: 22016143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient outcomes associated with group and individual genetic counseling formats.
    Rothwell E; Kohlmann W; Jasperson K; Gammon A; Wong B; Kinney A
    Fam Cancer; 2012 Mar; 11(1):97-106. PubMed ID: 22057473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.
    Høberg-Vetti H; Bjorvatn C; Fiane BE; Aas T; Woie K; Espelid H; Rusken T; Eikesdal HP; Listøl W; Haavind MT; Knappskog PM; Haukanes BI; Steen VM; Hoogerbrugge N
    Eur J Hum Genet; 2016 Jun; 24(6):881-8. PubMed ID: 26350514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
    McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ
    Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral.
    Bellcross CA; Leadbetter S; Alford SH; Peipins LA
    Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):728-35. PubMed ID: 23371291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2.
    Adams I; Christopher J; Williams KP; Sheppard VB
    J Cancer Educ; 2015 Jun; 30(2):344-52. PubMed ID: 25301325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Implementing B-RST
    Wernke K; Bellcross C; Gabram S; Ali N; Stanislaw C
    Clin Breast Cancer; 2019 Aug; 19(4):e547-e555. PubMed ID: 31005475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
    Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
    Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Women's satisfaction with genetic counseling for hereditary breast-ovarian cancer: psychological aspects.
    Tercyak KP; Demarco TA; Mars BD; Peshkin BN
    Am J Med Genet A; 2004 Nov; 131(1):36-41. PubMed ID: 15389697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.
    de Juan Jiménez I; García Casado Z; Palanca Suela S; Esteban Cardeñosa E; López Guerrero JA; Segura Huerta Á; Chirivella González I; Sánchez Heras AB; Juan Fita MJ; Tena García I; Guillen Ponce C; Martínez de Dueñas E; Romero Noguera I; Salas Trejo D; Goicoechea Sáez M; Bolufer Gilabert P
    Fam Cancer; 2013 Dec; 12(4):767-77. PubMed ID: 23479189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pre-visit tailored website enhances counselees' realistic expectations and knowledge and fulfils information needs for breast cancer genetic counselling.
    Albada A; van Dulmen S; Lindhout D; Bensing JM; Ausems MG
    Fam Cancer; 2012 Mar; 11(1):85-95. PubMed ID: 21901499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community attitudes towards a Jewish community BRCA1/2 testing program.
    Cousens N; Kaur R; Meiser B; Andrews L
    Fam Cancer; 2017 Jan; 16(1):17-28. PubMed ID: 27480161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer worry among Norwegian male BRCA1/2 mutation carriers.
    Strømsvik N; Råheim M; Gjengedal E
    Fam Cancer; 2011 Sep; 10(3):597-603. PubMed ID: 21603983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
    DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
    Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
    Hartge P; Struewing JP; Wacholder S; Brody LC; Tucker MA
    Am J Hum Genet; 1999 Apr; 64(4):963-70. PubMed ID: 10090881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2005 Mar; 133A(2):165-9. PubMed ID: 15633195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake of genetic counseling and multi-gene panel testing among women in the Intermountain West with previous negative BRCA1 and BRCA2 results contacted for updated testing.
    Mooney R; Espinel W; Elrick A; Kehoe K; Kohlmann W; Kaphingst KA
    J Genet Couns; 2022 Apr; 31(2):470-478. PubMed ID: 34570943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.